Cargando…

Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone‐only pill

INTRODUCTION: Approximately 100 million women currently use combined oral contraceptives. Combined oral contraceptives use is associated with increased risk of venous thromboembolic events and cardiovascular disease. Progestin‐only pills do not increase the risk of venous thromboembolic events, stro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palacios, Santiago, Colli, Enrico, Regidor, Pedro‐Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Gynecology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186823/ https://www.ncbi.nlm.nih.gov/pubmed/31321765 http://dx.doi.org/10.1111/aogs.13688

Ejemplares similares

A multicenter, double-blind, randomized trial on the bleeding profile of a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg
por: Palacios, Santiago, et al.
Publicado: (2019)

Efficacy and cardiovascular safety of the new estrogen-free contraceptive pill containing 4 mg drospirenone alone in a 24/4 regime
por: Palacios, Santiago, et al.
Publicado: (2020)

Correction to: A multicenter, double-blind, randomized trial on the bleeding profle of a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg
por: Palacios, Santiago, et al.
Publicado: (2020)

Bleeding profile of women using a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg
por: Palacios, S., et al.
Publicado: (2020)

Pharmacological and metabolic effects of drospirenone as a progestin-only pill compared to combined formulations with estrogen
por: Regidor, Pedro-Antonio, et al.
Publicado: (2023)

Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg Drospirenone
por: Römer, Thomas, et al.
Publicado: (2021)

A 1-year prospective, open-label, single-arm, multicenter, phase 3 trial of the contraceptive efficacy and safety of the oral progestin-only pill drospirenone 4 mg using a 24/4-day regimen()()
por: Kimble, Thomas, et al.
Publicado: (2020)

Correction: Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg Drospirenone
por: Römer, Thomas, et al.
Publicado: (2021)

Evaluation of the food effect on a drospirenone only contraceptive containing 4 mg administered with and without high-fat breakfast in a randomised trial
por: Regidor, P.-A., et al.
Publicado: (2022)

A single-arm study to evaluate the transfer of drospirenone to breast milk after reaching steady state, following oral administration of 4 mg drospirenone in healthy lactating female volunteers
por: Melka, Dace, et al.
Publicado: (2020)

Safety, efficacy, actions, and patient acceptability of drospirenone/ethinyl estradiol contraceptive pills in the treatment of premenstrual dysphoric disorder
por: Breech, Lesley L, et al.
Publicado: (2010)

The benefits of estetrol addition to drospirenone for contraception
por: Foidart, Jean Michel, et al.
Publicado: (2023)

Contraceptive Method Switching and Long-Acting Reversible Contraception Removal in U.S. Safety Net Clinics, 2016–2021
por: Darney, Blair G., et al.
Publicado: (2023)

Estetrol/Drospirenone: A Review in Oral Contraception
por: Lee, Arnold, et al.
Publicado: (2022)

Efficacy and safety of combined ethinyl estradiol/drospirenone oral contraceptives in the treatment of acne
por: Tan, Jerry KL, et al.
Publicado: (2010)

Correction: Estetrol/Drospirenone: A Review in Oral Contraception
por: Lee, Arnold, et al.
Publicado: (2022)

Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestogens: dienogest and drospirenone
por: Regidor, Pedro-Antonio, et al.
Publicado: (2017)

Estetrol‐Drospirenone combination oral contraceptive: a clinical study of contraceptive efficacy, bleeding pattern and safety in Europe and Russia
por: Gemzell‐Danielsson, K, et al.
Publicado: (2021)

Contraceptive Provision to Women With Intellectual and Developmental Disabilities Enrolled in Medicaid
por: Mitchell, Lauren, et al.
Publicado: (2023)

Drospirenone-containing oral contraceptives and venous thromboembolism: an analysis of the FAERS database
por: Madigan, David, et al.
Publicado: (2018)

Low Thrombin Generation in Users of a Contraceptive Containing Estetrol and Drospirenone
por: Morimont, Laure, et al.
Publicado: (2022)

Efficacy and safety of a 24-day regimen of drospirenone-containing combined oral contraceptive in Korean women
por: Kim, Nayoung, et al.
Publicado: (2015)

THE CONTRACEPTIVE PILL
Publicado: (1965)

Use of hormonal contraceptives among immigrant women and their daughters in Norway: Data from the Norwegian Prescription Database
por: Diaz, Esperanza, et al.
Publicado: (2018)

Bone health in estrogen-free contraception
por: Hadji, P., et al.
Publicado: (2019)

Drospirenone and mood
por: Zuschmann, Andrew
Publicado: (2022)

Correction to: Bone health in estrogen-free contraception
por: Hadji, P., et al.
Publicado: (2020)

Analysis of Complications and Management After Self-Administration of Medical Termination of Pregnancy Pills
por: Rath, Sudhansu, et al.
Publicado: (2021)

Vitamin D serum levels in women using contraception containing drospirenone – a preliminary study
por: Ciebiera, Michał, et al.
Publicado: (2017)

The association between drospirenone and hyperkalemia: a comparative-safety study
por: Bird, Steven T, et al.
Publicado: (2011)

Experience with oral emergency contraception since the OTC switch in Germany
por: Kiechle, Marion, et al.
Publicado: (2016)

A Comparative Efficacy of Low-Dose Combined Oral Contraceptives Containing Desogestrel and Drospirenone in Premenstrual Symptoms
por: Wichianpitaya, Jirath, et al.
Publicado: (2013)

Endometrial sampling before or after saline contrast sonohysterography in women with postmenopausal bleeding (ESPRESSO trial): A multicenter randomized controlled trial
por: Vroom, Albertine J., et al.
Publicado: (2021)

Contraceptive efficacy and tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomised, controlled study
por: Klipping, Christine, et al.
Publicado: (2012)

An Unusual, Delayed Presentation of a Migrated Intrauterine Contraceptive Device Into the Rectosigmoid Colon
por: Toh, Wuen Lynn, et al.
Publicado: (2023)

Health Status Is Affected, and Phase I/II Biotransformation Activity Altered in Young Women Using Oral Contraceptives Containing Drospirenone/Ethinyl Estradiol
por: Venter, Gerda, et al.
Publicado: (2021)

The Effect of Estetrol/Drospirenone on Ovarian Function Is Similar to a Well-Established Combined Oral Contraceptive: Results From a Phase 2 Study
por: Duijkers, Ingrid J M, et al.
Publicado: (2021)

Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial
por: Neal-Perry, Genevieve, et al.
Publicado: (2023)

Acute Ulnar Neuropathy After Uncomplicated Contraceptive Implant Insertion: A Case Report
por: Hussain, S Ahmed, et al.
Publicado: (2022)

Investigation of Laboratory and Clinical Features of Primary Dysmenorrhea: Comparison of Magnesium and Oral Contraceptives in Treatment
por: Gök, Soner, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e5ffhhocavjg12ib64vomn4fgj